Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer’s Disease and Related Disorders

@inproceedings{David2010MeasurementON,
  title={Measurement of Neuropsychiatric Symptoms in Clinical Trials Targeting Alzheimer’s Disease and Related Disorders},
  author={Renaud David and Emmanuel Mulin and Patrick Mall{\'e}a and Philippe H. Robert},
  booktitle={Pharmaceuticals},
  year={2010}
}
Behavioral and psychological symptoms (BPSD) are now known to be frequently associated to cognitive and functional decline in Alzheimer's disease and related disorders. They are present since the early stages of the disease and have negative impact on the disease process. BPSD assessment is crucial in clinical practice and also in future clinical trials… CONTINUE READING